Here we will be discussing the immune response to SARS‑CoV2, both in the context of natural exposure to the virus as well as induced immunity from vaccination. Several publications have reported the varying duration of acquired immunity. We will review these reports and discuss numerous factors that contribute to the longevity and duration of such immunity, by discussing some of the underlying mechanisms of the adaptive immune response, including lymphocyte activity, cytokine and chemokine activity, as well as the effects of pre‑existing conditions and immune history. Additionally, we will investigate the relationship between symptom severity and the longevity of acquired immunity.
You will learn about:
- SARS‑CoV‑2 virion and ACE2 binding
- Initiation of the adaptive response
- T‑ and B‑lymphocyte maturity
- B‑lymphocyte conversion to memory and plasma cells
- Factors that affect the duration of acquired immunity
Kenneth Oh, PhD,
Collaborations, Applications, and New Technology Senior Global Manager
Kenneth Oh earned his PhD in bioorganic chemistry at UC Santa Barbara, where he synthesized fluorescence‑based peptide beacons that measured nucleic acid and protein binding events. Upon graduation, he co‑founded a biotech company that re‑engineered virus capsids that served as a drug delivery platform. At Bio‑Rad, he develops product applications, establishes collaborations with researchers, and investigates new protein quantitation research tools.
Kelly King, PhD,
Field Application Specialist
Kelly King is currently a Field Application Specialist at Bio‑Rad Laboratories in the Mid‑Atlantic region. She has 12 years’ experience with Chromatography as well as specializing in Bio‑Plex Immunoassays and Western Blotting. Kelly joined Bio‑Rad 2 years ago after completing her Postdoctoral Fellowship at the US Naval Research Laboratory in Washington DC where she studied and characterized peptide-nanoparticle‑drug conjugates. Kelly earned her PhD from Lehigh University in Bethlehem, PA where she developed novel peptide conjugates to specifically target and deliver small therapeutic molecules and peptides to cancer cells.
Brad VanderWielen, PhD,
Field Application Specialist
Brad VanderWielen is currently a Field Application Specialist for Bio‑Rad Laboratories in the South‑Central region of the United States. He specializes in Chromatography, Western Blotting, and Bio‑Plex Multiplex ELISA instrumentation and associated experiments. He has been at Bio‑Rad for 5 years and has been in the field of Chromatography for the past 13 years. He came to Bio‑Rad from his postdoctoral work at UTSouthwestern Medical School where he was utilizing biophysics and X‑Ray crystallography to study tubulin regulation. Brad earned his PhD from the University of Cincinnati where he researched Notch transcriptional regulation utilizing biophysical applications and X‑Ray crystallography.
Global Marketing Manager, Immunoassays
Candice Cox is the Global Marketing Manager for the Immunoassay Group at Bio-Rad Laboratories. She graduated with a BSc in Biology from the University of California Los Angeles with a minor in English. She has been in several roles serving the pharmaceutical and life science industries, starting her career at Berlex Biosciences then joining Bio-Rad in 2004. At Bio-Rad she has held different roles in various groups, including R&D assay development, regional marketing, commercialization and new product development marketing for different product lines within the Life Science Group.